Literature DB >> 12019169

Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray.

Haiyong Han1, David J Bearss, L Walden Browne, Robert Calaluce, Raymond B Nagle, Daniel D Von Hoff.   

Abstract

To identify new diagnostic markers and drug targets for pancreatic cancer, we compared the gene expression patterns of pancreatic cancer cell lines growing in tissue culture with those of normal pancreas using cDNA microarray analysis. Fluorescently (cyanine 5) labeled cDNA probes, made individually from mRNA samples of nine pancreatic cell lines, were each combined with fluorescently (cyanine 3) labeled universal reference mRNA. The mixed probes of each sample were then hybridized with 5760 cDNA arrays (5289 unique cDNA sequences) printed on individual microscope slides. Fluorescently (cyanine 5) labeled normal pancreas mRNA was also compared with the same universal reference mRNA reference pool. The expression ratios of neoplastic versus normal pancreas cells were then calculated by multiplying the ratio of cancer versus the universal reference mRNA and the ratio of the universal reference mRNA cell versus normal pancreas. For 5289 different genes interrogated by the arrays, 30 of them showed an expression ratio 2 SD from the mean in at least three of the nine pancreatic cell lines studied. To confirm the expression profiles of these genes, quantitative reverse transcription-PCR and Northern blot were carried out for 25 of the overexpressed genes. To verify the overexpression in patient samples, two of the overexpressed genes, c-Myc and Rad51, were selected to undergo analysis by reverse transcription-PCR in frozen tumor tissues and by immunostaining in paraffin-embedded tissue section microarrays. The results of these experiments are in agreement with the microarray data. Potential up-regulated targets of note from this study include urokinase-type plasminogen activator receptor, serine/threonine kinase 15, thioredoxin reductase, and CDC28 protein kinase 2, as well as several others.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019169

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  116 in total

1.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 3.  Identifying molecular markers for the early detection of pancreatic neoplasia.

Authors:  Michael Goggins
Journal:  Semin Oncol       Date:  2007-08       Impact factor: 4.929

4.  Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer.

Authors:  Sally E Dowen; Tatjana Crnogorac-Jurcevic; Rathi Gangeswaran; Mikkel Hansen; Jyrki J Eloranta; Vipul Bhakta; Teresa A Brentnall; Jutta Lüttges; Gunther Klöppel; Nick R Lemoine
Journal:  Am J Pathol       Date:  2005-01       Impact factor: 4.307

5.  HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Authors:  Shanthi Adimoolam; Mint Sirisawad; Jun Chen; Patti Thiemann; James M Ford; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

6.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 7.  The consequences of Rad51 overexpression for normal and tumor cells.

Authors:  Hannah L Klein
Journal:  DNA Repair (Amst)       Date:  2008-02-01

Review 8.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

9.  Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer.

Authors:  Zhimin Tong; Ajaikumar B Kunnumakkara; Huamin Wang; Yoichi Matsuo; Parmeswaran Diagaradjane; Kuzhuvelil B Harikumar; Vijaya Ramachandran; Bokyung Sung; Arup Chakraborty; Robert S Bresalier; Craig Logsdon; Bharat B Aggarwal; Sunil Krishnan; Sushovan Guha
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  Restoration of silenced Peutz-Jeghers syndrome gene, LKB1, induces apoptosis in pancreatic carcinoma cells.

Authors:  Suparna Qanungo; Subrata Haldar; Aruna Basu
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.